Literature DB >> 18601792

Key principles for the improved conduct of health technology assessments for resource allocation decisions.

Michael F Drummond1, J Sanford Schwartz, Bengt Jönsson, Bryan R Luce, Peter J Neumann, Uwe Siebert, Sean D Sullivan.   

Abstract

Health technology assessment (HTA) is a dynamic, rapidly evolving process, embracing different types of assessments that inform real-world decisions about the value (i.e., benefits, risks, and costs) of new and existing technologies. Historically, most HTA agencies have focused on producing high quality assessment reports that can be used by a range of decision makers. However, increasingly organizations are undertaking or commissioning HTAs to inform a particular resource allocation decision, such as listing a drug on a national or local formulary, defining the range of coverage under insurance plans, or issuing mandatory guidance on the use of health technologies in a particular healthcare system. A set of fifteen principles that can be used in assessing existing or establishing new HTA activities is proposed, providing examples from existing HTA programs. The principal focus is on those HTA activities that are linked to, or include, a particular resource allocation decision. In these HTAs, the consideration of both costs and benefits, in an economic evaluation, is critical. It is also important to consider the link between the HTA and the decision that will follow. The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making."

Mesh:

Year:  2008        PMID: 18601792     DOI: 10.1017/S0266462308080343

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  78 in total

Review 1.  International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Authors:  Adrian R Levy; Craig Mitton; Karissa M Johnston; Brian Harrigan; Andrew H Briggs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Comparative effectiveness research: the view from a pharmaceutical company.

Authors:  Marc L Berger; David Grainger
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  EBM, HTA, and CER: clearing the confusion.

Authors:  Bryan R Luce; Michael Drummond; Bengt Jönsson; Peter J Neumann; J Sanford Schwartz; Uwe Siebert; Sean D Sullivan
Journal:  Milbank Q       Date:  2010-06       Impact factor: 4.911

4.  Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C.

Authors:  Gaby Sroczynski; Uwe Siebert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-20       Impact factor: 46.802

5.  Health technology assessments in England: an analysis of the NICE Medical Technologies Evaluation Programme.

Authors:  William Green; John Hutton
Journal:  Eur J Health Econ       Date:  2013-11-10

6.  Transparency in evidence evaluation and formulary decision-making: from conceptual development to real-world implementation.

Authors:  Bonnie B Dean; Kelly J Ko; Jennifer S Graff; A Russell Localio; Rolin Wade; Robert W Dubois
Journal:  P T       Date:  2013-08

7.  Economic analysis of nutrition interventions for chronic disease prevention: methods, research, and policy.

Authors:  John B Wong; Paul M Coates; Robert M Russell; Johanna T Dwyer; James A Schuttinga; Barbara A Bowman; Sarah A Peterson
Journal:  Nutr Rev       Date:  2011-09       Impact factor: 7.110

8.  The future of health technology assessment in healthcare decision making in Asia.

Authors:  Bong-Min Yang
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  Two decades of off-label prescribing in children: a literature review.

Authors:  Shamala Balan; Mohamed Azmi Ahmad Hassali; Vivienne S L Mak
Journal:  World J Pediatr       Date:  2018-09-14       Impact factor: 2.764

10.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal:  Cost Eff Resour Alloc       Date:  2010-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.